

Viktor GrÃ¼nwald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8178566/publications.pdf>

Version: 2024-02-01

151
papers

6,469
citations

159585

30
h-index

71685

76
g-index

182
all docs

182
docs citations

182
times ranked

7793
citing authors

#	ARTICLE	IF	CITATIONS
1	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1289-1300.	27.0	956
2	Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 706-720.	1.2	750
3	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1370-1385.	10.7	594
4	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. <i>Cancer Treatment Reviews</i> , 2016, 45, 7-18.	7.7	354
5	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1104-1115.	10.7	325
6	An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PATients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). <i>Annals of Oncology</i> , 2017, 28, 2399-2408.	1.2	274
7	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 286-296.	10.7	239
8	Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 297-310.	10.7	207
9	Efficacy of BCG398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. <i>Cancer Discovery</i> , 2018, 8, 812-821.	9.4	206
10	Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 994-1003.	10.7	194
11	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
12	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. <i>European Journal of Cancer</i> , 2017, 87, 147-163.	2.8	108
13	Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis. <i>European Urology</i> , 2009, 55, 1430-1439.	1.9	87
14	An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. <i>European Journal of Cancer</i> , 2012, 48, 324-332.	2.8	84
15	Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 "CREATE"™. <i>Annals of Oncology</i> , 2017, 28, 3000-3008.	1.2	70
16	Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2015, 26, 1372-1377.	1.2	69
17	Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. <i>European Journal of Cancer</i> , 2016, 69, 226-235.	2.8	65
18	Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. <i>Cancer Treatment Reviews</i> , 2016, 50, 109-117.	7.7	64

#	ARTICLE	IF	CITATIONS
19	Depth of Remission is a Prognostic Factor for Survival in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2015, 67, 952-958.	1.9	61
20	An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. <i>Nature Reviews Urology</i> , 2018, 15, 511-521.	3.8	61
21	Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 3555-3564.	1.6	56
22	TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). <i>Annals of Oncology</i> , 2015, 26, 561-567.	1.2	55
23	Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3012-3022.	7.0	48
24	Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2017, 19, 14.	4.0	46
25	DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies. <i>PLoS ONE</i> , 2014, 9, e91440.	2.5	42
26	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , 2019, 15, 929-941.	2.4	40
27	Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 499-503.	1.9	39
28	Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study. <i>Oral Oncology</i> , 2020, 102, 104526.	1.5	37
29	Efficacy of Sunitinib Re-Exposure after Failure of an mTOR Inhibitor in Patients with Metastatic RCC. <i>Onkologie</i> , 2011, 34, 310-314.	0.8	36
30	Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. <i>British Journal of Cancer</i> , 2020, 123, 898-904.	6.4	36
31	The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 â€“CREATEâ€™. <i>European Journal of Cancer</i> , 2018, 94, 156-167.	2.8	35
32	New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. <i>Journal of Clinical Medicine</i> , 2020, 9, 565.	2.4	35
33	The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 338-348.	3.7	34
34	Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). <i>Medical Oncology</i> , 2016, 33, 80.	2.5	32
35	Controversies in renal cell carcinoma: Treatment choice after progression on vascular endothelial growth factor-targeted therapy. <i>European Journal of Cancer</i> , 2014, 50, 1321-1329.	2.8	31
36	Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma â€“ An analysis of the EORTC 62012 study of the EORTC STBSG. <i>European Journal of Cancer</i> , 2016, 64, 44-51.	2.8	31

#	ARTICLE	IF	CITATIONS
37	Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. <i>British Journal of Cancer</i> , 2011, 105, 1635-1639.	6.4	29
38	Practical Management of Everolimus-Related Toxicities in Patients with Advanced Solid Tumors. <i>Onkologie</i> , 2013, 36, 295-302.	0.8	29
39	Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. <i>Acta Oncologica</i> , 2017, 56, 1013-1020.	1.8	29
40	A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 312.	1.6	28
41	Vorinostat in refractory soft tissue sarcomas – Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). <i>European Journal of Cancer</i> , 2016, 64, 74-82.	2.8	28
42	Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey. <i>Oncologist</i> , 2018, 23, 461-467.	3.7	27
43	Molecular Imaging in Oncology Using Positron Emission Tomography. <i>Deutsches A&#x0308;rztblatt International</i> , 2018, 115, 175-181.	0.9	27
44	Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care – Registry data from an outcomes research project of the German Testicular Cancer Study Group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 168.e21-168.e28.	1.6	25
45	Managing Side Effects of Angiogenesis Inhibitors in Renal Cell Carcinoma. <i>Oncology Research and Treatment</i> , 2007, 30, 519-524.	1.2	24
46	Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma – Analysis Using Diagnostic Nodes. <i>Oncologist</i> , 2015, 20, 1028-1035.	3.7	23
47	Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2016, 70, 1006-1015.	1.9	23
48	Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment. <i>OncoTargets and Therapy</i> , 2012, 5, 111.	2.0	22
49	Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?. <i>Medical Oncology</i> , 2016, 33, 59.	2.5	22
50	Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer. <i>BJU International</i> , 2021, 127, 44-55.	2.5	22
51	The Diagnosis, Treatment, and Follow-up of Renal Cell Carcinoma. <i>Deutsches A&#x0308;rztblatt International</i> , 2016, 113, 590-6.	0.9	21
52	Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).. <i>Journal of Clinical Oncology</i> , 2021, 39, 269-269.	1.6	21
53	PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 88-91.	5.0	21
54	Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach. <i>World Journal of Urology</i> , 2010, 28, 343-351.	2.2	20

#	ARTICLE	IF	CITATIONS
73	Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.. Journal of Clinical Oncology, 2021, 39, 313-313.	1.6	8
74	A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS706-TPS706.	1.6	8
75	T-cell checkpoint inhibitors in metastatic renal cell carcinoma. Current Opinion in Urology, 2015, 25, 411-415.	1.8	7
76	Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohort. World Journal of Urology, 2018, 36, 1423-1429.	2.2	7
77	Radiological Monitoring of Modern Immunotherapy: A Novel Challenge for Interdisciplinary Patient Care. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2020, 192, 235-245.	1.3	7
78	Everolimus after failure of one prior VEGF targeted therapy in metastatic renal cell carcinoma: Final results of the MARC 2 trial. International Journal of Cancer, 2021, 148, 1685-1694.	5.1	7
79	What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature. Current Opinion in Urology, 2021, 31, 276-284.	1.8	7
80	Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis. Journal of Kidney Cancer and VHL, 2017, 4, 8-15.	1.0	7
81	Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors. Molecular and Clinical Oncology, 2020, 13, 1-1.	1.0	7
82	Checkpoint Blockade - a New Treatment Paradigm in Renal Cell Carcinoma. Oncology Research and Treatment, 2016, 39, 353-358.	1.2	6
83	Therapy of Treatment-Related Hypertension in Metastatic Renal-Cell Cancer Patients Receiving Sunitinib. Clinical Genitourinary Cancer, 2017, 15, 280-290.e3.	1.9	6
84	Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG). BMJ Open, 2020, 10, e035546.	1.9	6
85	718P A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment. Annals of Oncology, 2020, 31, S564.	1.2	6
86	The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 296.e11-296.e19.	1.6	6
87	Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?. World Journal of Urology, 2016, 34, 909-915.	2.2	5
88	Renal cell carcinoma in kidney transplant recipients: descriptive analysis and overview of a major German transplant center. Future Oncology, 2019, 15, 3739-3750.	2.4	5
89	First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial. International Journal of Cancer, 2021, 148, 950-960.	5.1	5
90	Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. British Journal of Cancer, 2021, 124, 721-727.	6.4	5

#	ARTICLE	IF	CITATIONS
91	Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy. , 2021, 9, e002262.		5
92	Final results of patients with metastatic renal cell carcinoma treated with MGN1601 in the ASET study.. Journal of Clinical Oncology, 2014, 32, e15590-e15590.	1.6	5
93	Systemic therapy of renal cell carcinoma. World Journal of Urology, 2014, 32, 1-1.	2.2	4
94	Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214. Annals of Oncology, 2018, 29, viii309-viii310.	1.2	4
95	Systemic treatment of advanced/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N). Journal of Cancer Research and Clinical Oncology, 2020, 146, 3075-3078.	2.5	4
96	Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy. World Journal of Urology, 2016, 34, 1239-1245.	2.2	3
97	Proof of principle for bevacizumab activity in desmoid-type fibromatosis. Clinical Sarcoma Research, 2016, 6, 5.	2.3	3
98	A phase III, randomized, placebo-controlled trial of adjuvant nivolumab plus ipilimumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after radical or partial nephrectomy (CheckMate 914). Annals of Oncology, 2018, 29, viii330.	1.2	3
99	Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab. Frontiers in Oncology, 2021, 11, 635096.	2.8	3
100	Patient-reported outcomes in a randomized trial of everolimus with metastatic renal cell carcinoma patients. Journal of Clinical Oncology, 2009, 27, e17516-e17516.	1.6	3
101	Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group. World Journal of Urology, 2022, 40, 2381-2386.	2.2	3
102	Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients. World Journal of Urology, 2010, 28, 311-317.	2.2	2
103	Role of immunohistochemistry and fluorescence in-situ hybridization (FISH) in the diagnosis of spindle and round cell tumors of the kidney. Journal of the Egyptian National Cancer Institute, 2015, 27, 173-178.	1.5	2
104	CT patterns of organizing pneumonia in patients treated with VEGF/mTOR inhibitors for metastatic renal cell cancer: an observational study. Acta Radiologica Open, 2017, 6, 205846011769421.	0.6	2
105	The role of nephrectomy in metastatic renal cell carcinoma. Nature Reviews Nephrology, 2018, 14, 601-602.	9.6	2
106	Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Open-label, Dose-finding and Dose-expansion, Phase 1b Trial. European Urology, 2019, 75, 697-698.	1.9	2
107	Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. Kidney Cancer, 2020, 4, 29-39.	0.4	2
108	Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). Cancers, 2021, 13, 2594.	3.7	2

#	ARTICLE	IF	CITATIONS
109	Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): Results of a multi-center randomized phase II AIO trial.. Journal of Clinical Oncology, 2019, 37, 4120-4120.	1.6	2
110	Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL.. Journal of Clinical Oncology, 2019, 37, 4574-4574.	1.6	2
111	A randomized phase II trial comparing switch to nivolumab with TKI continuation after 12 weeks of TKI induction therapy in metastatic renal cell carcinoma patients (NIVOSWITCH).. Journal of Clinical Oncology, 2020, 38, 678-678.	1.6	2
112	CaboPoint, a phase II, open-label study of cabozantinib as second-line therapy for patients with clear cell metastatic renal cell carcinoma (RCC), whose disease progressed after therapy with checkpoint inhibitors (CPIs).. Journal of Clinical Oncology, 2020, 38, TPS772-TPS772.	1.6	2
113	A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS 0415).. Journal of Clinical Oncology, 2019, 37, TPS11075-TPS11075.	1.6	2
114	Acral Necrosis after Inadequate Excessive Administration of Bleomycin in a Testicular Cancer Patient. Oncology Research and Treatment, 2005, 28, 41-43.	1.2	1
115	2598 Early tumor shrinkage (eTS) - a novel endpoint for clinical studies in metastatic renal cell carcinoma (mRCC). European Journal of Cancer, 2015, 51, S510-S511.	2.8	1
116	Collection of real-world data on nivolumab's effectiveness in renal cell carcinoma: rationale for an observational study. Future Oncology, 2018, 14, 1023-1034.	2.4	1
117	Quality of life in patients with soft tissue sarcoma undergoing palliative treatment: A multicenter, cluster-randomized trial within the Germany Interdisciplinary Sarcoma Group (GISG-12). Annals of Oncology, 2018, 29, viii578.	1.2	1
118	Sarcoid-Like Lesions Mimicking Pulmonary Metastasis: A Case Series and Review of the Literature. Oncology Research and Treatment, 2019, 42, 382-386.	1.2	1
119	Real world data on the use of nivolumab and ipilimumab combination therapy or nivolumab monotherapy in the treatment of renal cell carcinoma: Interim results from the non-interventional study (NIS) NORA. European Urology Open Science, 2020, 19, e1107.	0.4	1
120	Are we ready to accept intermediate outcome measures in clinical cancer trials?. Annals of Oncology, 2020, 31, 973-975.	1.2	1
121	1669TiP A non-randomized, open-label phase II trial evaluating efficacy and feasibility of combined treatment with trabectedin and nivolumab in patients with metastatic or inoperable soft tissue sarcomas (STS) after failure of an anthracycline-containing regimen. Annals of Oncology, 2020, 31, S991.	1.2	1
122	Overall survival analysis from a randomized phase II study of axitinib with or without dose titration for first-line metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 4545-4545.	1.6	1
123	Effect of crizotinib on disease control in patient with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification: Final results of EORTC 90101 CREATE.. Journal of Clinical Oncology, 2018, 36, 580-580.	1.6	1
124	Everolimus in patients with metastatic renal cell carcinoma (mRCC) who are intolerant of or have progressed after prior vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) therapy: An international expanded access program (EAP).. Journal of Clinical Oncology, 2011, 29, 314-314.	1.6	1
125	MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy.. Journal of Clinical Oncology, 2012, 30, 467-467.	1.6	1
126	Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, 4570-4570.	1.6	1

#	ARTICLE	IF	CITATIONS
127	Sequential treatment with pazopanib followed by nivolumab in patients with renal cell carcinoma: Updated interim results of the non-interventional study PAZOREAL.. Journal of Clinical Oncology, 2020, 38, e17075-e17075.	1.6	1
128	Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFICID Trial. Oncology Research and Treatment, 2022, 45, 319-325.	1.2	1
129	Interim results from PAZOREAL: A non-interventional study to assess effectiveness and safety of pazopanib and everolimus in the changing mRCC treatment landscape. Annals of Oncology, 2017, 28, v318-v319.	1.2	0
130	Aiming for complete responses in renal-cell carcinoma. Lancet Oncology, The, 2018, 19, 428-429.	10.7	0
131	Health-related quality of life (HR-QoL) in elderly soft tissue sarcoma (STS) patients from the randomized phase II EPAZ study comparing pazopanib (PAZ) and doxorubicin (DOX) in first line. Annals of Oncology, 2018, 29, viii577.	1.2	0
132	Metastatic Liposarcoma: A Case of Partial Remission with Eribulin in Late Treatment Lines. Journal of Clinical Case Reports, 2018, 08, .	0.0	0
133	Efficacy and safety of pazopanib in patients with advanced and/or metastatic renal cell carcinoma (mRCC) after previous checkpoint inhibitor treatment. European Urology Supplements, 2018, 17, e2957.	0.1	0
134	Real world evidence in renal cell carcinoma: A national, prospective, non-interventional study of nivolumab in patients with advanced renal cell carcinoma after prior therapy (NORA). European Urology Supplements, 2019, 18, e1841.	0.1	0
135	A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH). Annals of Oncology, 2019, 30, v388.	1.2	0
136	Advanced renal cell carcinoma: First results from the prospective research platform CARAT for patients with mRCC in Germany. Annals of Oncology, 2019, 30, v392.	1.2	0
137	Soft tissue sarcomas express a distinct mRNA immune profile. Annals of Oncology, 2019, 30, v702.	1.2	0
138	Reply to E. Younger et al, V. Sharma et al, and M. Uchihara et al. Journal of Clinical Oncology, 2021, 39, 864-865.	1.6	0
139	Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell Carcinoma. European Urology, 2021, 80, 256-257.	1.9	0
140	High response to docetaxel (D)/carboplatin (C) based chemotherapy as salvage therapy in patients with docetaxel-resistant metastatic hormone-refractory prostate cancer (HRPC). Journal of Clinical Oncology, 2009, 27, e16041-e16041.	1.6	0
141	Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. Journal of Clinical Oncology, 2013, 31, 152-152.	1.6	0
142	Effectiveness of abiraterone as salvage therapy in patients with docetaxel- and castration-resistant prostate cancer (mDCPC) that progressed during second-line chemotherapy with carboplatin plus weekly docetaxel (DC).. Journal of Clinical Oncology, 2013, 31, e16064-e16064.	1.6	0
143	Late onset of bone metastases as a prognostic parameter in metastatic renal cell cancer (mRCC): A single-center experience in 82 mRCC patients treated with sunitinib.. Journal of Clinical Oncology, 2014, 32, 523-523.	1.6	0
144	Efficacy and safety of gemcitabine, oxaliplatin and paclitaxel (GOP) in cisplatin-refractory germ cell tumors in routine care: Registry data from an outcomes research project.. Journal of Clinical Oncology, 2015, 33, e15570-e15570.	1.6	0

#	ARTICLE	IF	CITATIONS
145	Translational study associated to a phase II study evaluating the activity of pazopanib in patients (pts) with advanced/metastatic liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) study.. Journal of Clinical Oncology, 2019, 37, 11067-11067.	1.6	0
146	A prospective, open label, multicenter, randomized phase II trial: Sequential therapy with bevacizumab, RAd001 (everolimus) and axitinib in metastatic renal cell carcinoma (mRCC) (BERAT study).. Journal of Clinical Oncology, 2019, 37, e16097-e16097.	1.6	0
147	Survival in metastatic renal cell carcinoma (mRCC) patients over two decades: Does age matter?. Journal of Clinical Oncology, 2020, 38, e17103-e17103.	1.6	0
148	Retrospective comparison of the different immune combinations in metastatic renal cell carcinoma. Annals of Translational Medicine, 2020, 8, 839-839.	1.7	0
149	Prognostic Impact of Lymphnode Metastases in Patients with Metastatic Renal Cell Carcinoma. Kidney Cancer, 2021, , 1-8.	0.4	0
150	Axitinib plus Immuncheckpoint-Inhibitor: evidenz- und expertenbasierte Konsensusempfehlungen für die Behandlungsoptimierung und das Management von therapieassoziierten Nebenwirkungen. Karger Kompass Onkologie, 2020, 7, 180-189.	0.0	0
151	A Prospectively Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study). Oncology Research and Treatment, 2022, 45, 272-280.	1.2	0